CONNECT WITH US
HealthTech

HealthTech

Type 1 and type 2 diabetes therapies show great promise—but treatment is only effective if people can access it

Medical Xpress logo

Published on

Add as a preferred source on Google
Type 1 and type 2 diabetes therapies show great promise—but treatment is only effective if people can access it

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

In 2026, over 830 million people worldwide are estimated to live with diabetes—more than ever before.

Most live in low- and middle-income countries, and over 90% live with type 2 diabetes, a condition where the body cannot use insulin properly. The second most common form of diabetes is type 1, caused by the immune system attacking insulin-producing cells.

A 2023 analysis used existing data to model the future burden of diabetes. It estimates that by 2050, more than 1.3 billion people will have diabetes. In North Africa and the Middle East, nearly 17% of people may be affected. In Latin America and the Caribbean, that number could be 11%. Diabetes increases risks of dying early as well as developing a range of complications, including eye, kidney and heart disease. It also affects mental health and well-being.

Despite these climbing numbers, there are plenty of reasons to be hopeful about the future of diabetes. I like to regularly remind myself of them, as a health care researcher who has lived with type 1 diabetes for over 30 years.

New treatments are on the horizon, and high-profile people with diabetes are speaking about the condition, raising awareness of the need for better treatments and access to care. S. S. Senate.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.